Surveillance and specific prevention of neumococcia in hospilalized infants (1994-200)

Su prevención específica (1994-2000)

  • María Hortal Universidad de la República, Programa de Desarrollo de las Ciencias Básicas (PEDECIBA), Prof. (de primer nivel). Facultad de Medicina, Departamento de Bacteriología y Virología, Ex Prof. Agregado. Programa OPS/SIREVA, Coordinador Nacional. Proyecto sobre Carga de Enfermedad de las Neumonías y Meningitis del Niño, Investigador principal
  • Teresa Camou Uruguay. Ministerio de Salud Pública, Departamento de Laboratorios, Bacteriólogo. Programa OPS/SIREVA, Investigador asociado
  • Rosario Palacio Uruguay. Ministerio de Salud Pública, Departamento de Laboratorios, Médico Infectólogo. Programa OPS/SIREVA, Investigador asociado
  • Gabriel Pérez-Giffoni Uruguay. Ministerio de Salud Pública, Departamento de Laboratorios, Médico Infectólogo. Universidad de la República, Facultad de Ciencias, Laboratorio de Microbiología, Docente titular grado 2
  • José Luis Di Fabio OPS, Washington, DC, EEUU, Programa especial de vacunas e inmunizaciones, Asesor en investigación, producción y control de calidad de vacunas
  • Grupo OPS/SIREVA- Uruguay OPS/SIREVA: Oficina Panamericana de la Salud/Sistema Regional de Vacunas
Keywords: VACCINES, PNEUMOCOCCAL INFECTIONS, STREPTOCOCCUS PNEUMONIAE, EPIDEMIOLOGICAL SURVEILLANCE, CHILD, ADOLESCENCE

Abstract

The aim of this paper are to promote available national information and to analyze the effects of the recently released vaccinations such as serum streptococcus pneumo-niae capsules in infants up to 14 years old.
During seven years (1994-2000) 520 isolate invaders were collected in patients with pneumonia (67%), meningitis (21%), bacteremia/sepsis (8%), and other processes (4%) such as peritonitis, osteomyelitis, cellulite, and abscess. Serotype distribution showed a global potentially coverage of 44% with heptavalent vaccine (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F), 77% with nonavalent vaccine (plus serotypes 1 and 5), and 86,9% with 11-valent vaccine (plus serotypes 3 and 7F). Antigenic combination with other serotypes not included in vaccines allows to estimate rate increase up to 53.2%, 86.5% and 95,7% respectively. In patients from 4 months to 5 years old, primary beneficiaries of recent vaccines, coverage rates ranged from 40% (2-5 years) to 67% (4-11 months), whereas nonavalent vaccine showed a better coverage, 78% to 86%. Coverage reached in patients with meningitis was lower compared to patients with pneumonia since serotype dispersion was higher.
Forty-three fatal cases (meningitis, 30 and pneumonia, 13) could have potentially been prevented in 67-70%, 73-78% and 93-100% with these new vaccines.
Strains with diminished susceptibility to penicillin, countrywide found, were more frequently isolated in cases of pneumonia (39%) than in cases of meningitis (12%). Overall coverage of any of these vaccines was 92% for intermediate resistant strains and 100% for high resistant strains.
In summary, considering cost effectiveness, nonava-lent vaccine appears to be as the best choice to prevent invasive pneumococcia, particularly in Uruguayan infants since it includes three of the most frequent serotypes found in this population at risk. Obviously, 11-valent vaccine may widen coverage in case costs were lower.

References

1) Musher DM. Infections caused by Streptococcus pneumoniae: clinical spectrum, pathogenesis, immunity and treatment. Rev Infect Dis 1992; 14: 801-7.
2) Ruocco G, Curto S, Savio M, Laurani H, Frocht R. Impacto y experiencia de vacunación contra Haemophilus influenzae tipo b. Rev Panam Salud Pública 1999; 5: 197-8.
3) Fedson DS, Musser MD. Pneumococcal vaccine. In: Plotkin SA, Mortimer EA Jr., eds. Vaccines. 2a ed. Philadelphia: WB Saunders, 1994: 517-63.
4) Shinefield HR, Black S. Efficacy of pneumococcal conjugate vaccines in large scale field trials. Pediatr Infect Dis J 2000; 19: 394-7.
5) Klein DL. Pneumococcal disease and the role of conjugate vaccines. Microb Drug Resist 1999; 5: 147-57.
6) Fenoll A, Jado I, Vicioso D, Pérez A, Casal J. Evolution of Streptococcus pneumoniae serotypes and antibiotic resistance in Spain: update (1990 to 1996). J Clin Microbiol 1998; 36: 3447-54.
7) Hausdorff WP, Bryant J, Kloek C, Paradiso PR, Siber GR. The contribution of specific pneumococcal serogroups to different disease manifestations: implications for conjugate vaccine formulation and use. Part II. Clin Infect Dis 2000; 30: 122-40.
8) Baquero F. Pneumococcal resistance to b-lactam antibiotics: a global geographic overview. Microb Drug Resist 1995; 1: 115-20.
9) Hortal M, Camou T, Fajardo C, Palacio R, Pallas C, Palma L, et al. Caracteres biológicos de Haemophilus influenzae aislados de diferentes poblaciones infantiles. Arch Pediatr Urug 1993; 64: 15-8.
10) Di Fabio JL, Homma A, De Quadros C. Pan American Health Organization Epidemiological surveillance network for Streptococcus pneumoniae Microb Drug Resist 1997; 2: 131-3.
11) Hortal M and the Pneumococcus study group. Capsular type distribution and susceptibility to antibiotics of Streptococcus pneumoniae Clinical strains isolated from Uruguayan children with systemic infections. Microb Drug Resist 1997; 2: 159-63.
12) Sorensen UBS. Typing of pneumococci by using 12 pooled sera. J Clin Microbiol 1993; 31: 2097-100.
13) Eskola J, Kilpi T, Palmu A, Jokinen J, Haapakoski J, Herva E, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344(6): 403-9.
14) National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Ninth information supplement M100- S9. Wayne: National Committee for Clinical Laboratory Standards, 1999: 52-4.
15) Hortal M, Mogdasy C, Russi JC, Deleón C, Suárez A. Microbial agents associated with pneumonia in children from Uruguay. Rev Infect Dis 1990; 12(8): S915-22.
16) Mulholland K. Strategies for the control of pneumococcal diseases. Vaccine 1999; 17: S 79-84.
17) Juven T, Mertsola J, Warris M, Leinonen M, Meurman O, Roivainen M, et al. Etiology of community-acquired pneumonia in 245 hospitalized children. Pediatr Infect Dis J 2000; 19: 293-8.
18) División Estadística del Ministerio de Salud Pública (Uruguay). Informe anual. Montevideo: MSP, 1999.
19) Gutiérrez C, Palenzuela S, Rodríguez A, Balbela B, Rubio I, Lenes A, et al. Muerte inesperada del lactante. Diagnóstico de situación en la ciudad de Montevideo. Arch Pediatr Uruguay 2001; 72: 185-97.
20) Castañeda E, Leal AL, Castillo O, De La Hoz F, Vela MC, Aramgo M, et al. Distribution of capsular types and antimicrobial susceptibility of invasive isolates of Streptococcus pneumoniae in Colombian children. Microb Drug Resist 1997; 3: 147-52.
21) Black S, Shinefield H, Fireman B, Lewis E, Ray P, Hansen JR, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J 2000; 19(3): 187-95.
22) Mulholland K. Maternal immunization for the prevention of bacterial infection in young infants. FRACP, Global Programme for Vaccines and Immunization. Geneve: WHO/VRD/GEN/, 1998.
23) Raymond J, Le Thomas I, Moulin F, Commeau A, Gendrel D, Berche P. Sequential colonization by Streptococcus pneumoniae of healthy children living in an orphanage. J Infect Dis 2000; 181: 1983-8.
24) Mogdasy C, Camou T, Fajardo C, Hortal M. Colonizing and invasive strains of Streptococcus pneumoniae in Uruguayan children: type distribution and patterns of antibiotic resistance. Pediat Infect Dis J 1992; 11: 648-52.
25) Hortal M, Palacio R, Camou T, Mogdasy C. Antimicrobial resistance in Streptococcus pneumoniae strains from Uruguay. Pediatr Infect Dis J 1994; 13: 542-3.
26) Camou T, Hortal M, Tomasz A. The apparent importation of penicillin resistant capsular type 14 Spanish/ French clone of Streptococcus pneumoniae into Uruguay in the early 1990s. Microb Drug Resist 1998; 4: 219-24.
27) Kertesz DA, Di Fabio JL, Brandileone MC, Castañeda E, Echaniz-Aviles G, Heitman I, et al. Invasive Streptococcus pneumoniae infection in Latin American children: results of the Pan American Health Organization surveillance study. Clin Infect Dis 1998; 26: 1355-61.
28) Di Fabio JL, Castañeda E, Agudelo CI, De la Hoz F, Hortal M, Camou T, et al. Evolution of Streptococcus pneumoniae serptypes and penicillin susceptibility in Latin America, SIREVA-Vigía Group.1993-1999. Pediatr Infect Dis J 2001; 20: 959-67.
29) Eskola J, Kilpi T, Palmu A. Efficacy of a pneumococal conjugate vaccine against acute otitis media. N Engl J Med 2001; 344: 403-9.
30) Scott JAG, May AJ, Dagan R, Dixon JMS, Eykyn SJ, Fenoll A, et al. Serogroup-specific epidemiology of Streptococcus pneumoniae: association with age, sex, and geography in 7.000 episodes of invasive disease. Clin Infect Dis 1996; 22: 973-81.
31) Hortal M, Lovgren M, De la Hoz F, Agudelo CL, Brandileone MC, Camou T, et al. Antibiotic resistance in Streptococcus pneumoniae in six Latin American countries: 1993-1999 surveillance. Microb Drug Resist 2001; 7: 391-401.
32) Hortal M, Camou T, Palacio R, Dibarboure H, García A. Ten-year review of invasive pneumococcal diseases in children and adults from Uruguay: clinical spectrum, serotypes and antimicrobial resistance. Int Infect Dis 2000; 4: 91-5.
33) Heffelfinger JD, Dowell SF, Jorgensen JH, Klugman KP, Mabry LR, Musher DM, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. Arch Intern Med 2000; 160: 1399-1408.
34) Pírez MC, Martínez O, Ferrari AM, Nairac A, Montano A, Rubio I, et al. Standard case management of pneumonia in hospitalized children in Uruguay, 1997 to 1998. Pedatr Infect Dis J 2001; 20: 283-9.
35) Briles DE, Hollingshead S, Brooks-Walter A, Nabors GS, Fergusson L, Schilling M, et al. The potential to use PspA and other pneumococcal proteins to elicit protection against pneumococcal infection. Vaccine 2000; 18: 1707-11.
Published
2002-05-31
How to Cite
1.
Hortal M, Camou T, Palacio R, Pérez-Giffoni G, Di Fabio JL, Uruguay GO-. Surveillance and specific prevention of neumococcia in hospilalized infants (1994-200). Rev. Méd. Urug. [Internet]. 2002May31 [cited 2024Nov.17];18(1):66-5. Available from: http://www2.rmu.org.uy/ojsrmu311/index.php/rmu/article/view/1003
Issue
Vol 18 No 1 (2002): Revista Médica del Uruguay
Section
Original Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.